Quality of Life Measurement Using Wrist Actigraphy in HCV Genotype 1 Infected, Treatment naïve Patients Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir Tablets and Dasabuvir Tablets (Viekirax®/Exviera®; 3D Regimen): The HEMATITE Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms The HEMATITE Study
- Sponsors AbbVie
- 14 Mar 2018 Planned End Date changed from 31 Jan 2018 to 31 Jul 2019.
- 14 Mar 2018 Planned primary completion date changed from 31 Jan 2018 to 31 Jul 2019.
- 27 Nov 2017 Status changed from recruiting to active, no longer recruiting.